Healio

Neurotrophic keratitis landscape improving, yet many hurdles remain

Please provide your email address to receive an email when new articles are posted on . Oxervate, approved by the FDA in 2018, treats the underlying cause of neurotrophic keratitis. Other treatment ...
Healio

Cornea specialists compare management approaches for neurotrophic keratitis

Please provide your email address to receive an email when new articles are posted on . Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and ...
PR Newswire

Neurotrophic Keratopathy Market to Grow Rapidly at a CAGR of 15.4% by 2032, Predicts DelveInsight

The dynamics of the neurotrophic keratopathy market are expected to increase in the forecast period. Compared to 2019, massive growth is expected in the 7MM neurotrophic keratopathy market. Along with ...
Ophthalmology Times

IRIS Registry data mined for understanding of pediatric NK

Searching the IRIS Registry for the years 2016 to 2022, they found data entered for 67,855,466 patients. Applying the ICD code for NK led to the identification of 47,700 cases of NK of which 429 ...
Business Insider

Dompé receives FDA approval of Oxervate™ eye drops (cenegermin-bkbj ophthalmic solution), first-in-class recombinant human nerve growth factor with potential to completely ...

MILAN and SAN BRUNO, Calif., Aug. 22, 2018 /PRNewswire/ -- Dompé today announced that the U.S. Food and Drug Administration (FDA) has approved Oxervate TM (cenegermin-bkbj ophthalmic solution), a ...
KTLA

RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)

ROCKVILLE, Md., Sept. 27, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair ...
Mena FN

Neurotrophic Keratitis Treatment Market In 2029

(MENAFN- EIN Presswire) EINPresswire/ -- Neurotrophic Keratitis Treatment Market to Surpass $5 billion in 2029. In comparison, the Central Nervous System Drugs market, which is considered as its ...
WIVB-TV

Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy

ROCKVILLE, Md., Jan. 3, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, ...
Medscape

Which Regenerative Methods Are Used for Healing the Cornea?

In ophthalmology, there are several approved, biotechnologically manufactured, regenerative medicine products that are used as eye drops or as transplants for corneal diseases. Gerd Geerling, MD, PhD, ...
ksn.com

RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis

ROCKVILLE, Md., July 18, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, ...
Nasdaq

First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259

ROCKVILLE, Md., April 13, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair ...
Nasdaq

Oyster Point Pharma Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial of OC-01 (varenicline) Nasal Spray for Patients with Neurotrophic Keratopathy

PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...